Q3 Results: Profit jumps 88% crore, earnings rise 70%, but stock still loses 6%

News Topical, Digital Desk : Q3 Results: Senores Pharmaceuticals Limited reported strong operational performance in the third quarter of FY26 (Q3 FY26). Despite this, the company's shares saw pressure during trading on Tuesday.
The company's net profit increased 88% year-on-year to ₹32 crore, compared to ₹17 crore in the same quarter last year. Revenue rose a sharp 69.4% to ₹174.5 crore. 

Sharp Improvement in EBITDA and Margins The company's EBITDA more than doubled to ₹54 crore in Q3 FY26 from ₹25.4 crore a year ago. EBITDA margins expanded from 25% to 31%, reflecting operating leverage and improved product mix. Cash flow from operations was approximately ₹19 crore in the quarter, bringing total operating cash flow for the nine months to approximately ₹51 crore. This is a significant improvement compared to the previous year. 

Strong Pipeline in Regulated Markets During the quarter, Senores further strengthened its pipeline in regulated markets. The company now has 46 approved ANDAs, comprising 137 strengths, with over 100 strengths pending launch. Additionally, 22 ANDAs (with over 50 strengths) are in development, which will support long-term growth. 

Record Performance in Emerging Markets The company recorded its highest-ever revenue and EBITDA in Emerging Markets this quarter. Revenue from this segment grew approximately 48% year-on-year, while EBITDA margins increased from approximately 1% in Q3 FY25 to 13%. Importantly, the Emerging Markets business became cash flow positive this quarter. 

Acquisitions and Expansion On the acquisition front, Senores has completed the first phase of the acquisition of Apnar Pharmaceuticals, acquiring a 75% stake in the company. The remaining 25% stake is planned to be acquired by Q2 FY27. Three of Apnar's five approved ANDAs are scheduled to be launched in Q4 FY26. According to the company, integration and scale-up are progressing faster than expected. 

Management Commentary The company's Managing Director Swapnil Shah said that growth was supported by new ANDA launches, expansion of manufacturing capacities and strong demand in branded generics, where earnings grew more than 6 times year-on-year. He further said that the company is on track to achieve full-year guidance. The focus will be on expanding the ANDA portfolio, scaling CDMO operations, improving profitability in emerging markets and growing the branded generics business in India. 

Share Status At 1:52 pm, Senores Pharmaceuticals shares were trading at ₹756.10, down over 6% on the NSE.

Read More: Q3 Results: Profit jumps 88% crore, earnings rise 70%, but stock still loses 6%